Abbott Strikes Deal With British Liquid Biopsy Company Angle

Abbott and UK-based Angle plc announced they will collaborate on a breast cancer liquid biopsy study, assessing Angle's technology for harvesting circulating tumor cells in combination with Abbott's FDA-approved gene-based test for determining HER-2 status.

More from Business

More from Medtech Insight